PH 1 TRIAL EVALUATING MRG‐106, A MICRORNA‐155 INHIBITOR, ADMINISTERED BY INTRATUMORAL, SUBCUTANEOUS, OR INTRAVENOUS DELIVERY IN CUTANEOUS T‐CELL LYMPHOMA (CTCL) PATIENTS. (June 2017)

• Record Type: Journal Article
• Authors: Querfeld, C.; Foss, F.M.; Porcu, P.; Kim, Y.H.; Pacheco, T.; Haverkos, B.; Halwani, A.S.; DeSimone, J.; William, B.; Pinter‐Brown, L.; Seto, A.; Ruckman, J.; Landry, M.; Jackson, A.L.; Dickinson, B.; Sanseverino, M.; Rodman, D.; Rubin, P.; Marshall, W.S.
• Is Part Of: Hematological oncology. Volume 35(2017)Supplement 2
• Page Start: 275
• Page End: 276
• Publication Date: 2017-06
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2438_149
• Languages: English
• ISSNs: 0278-0232